Veracyte Inc
VCYT
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
11.9% downsideOvervalued by 11.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.70 Billion |
|---|---|
| Enterprise Value | $3.44 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.84 |
| Beta | 1.93 |
| Outstanding Shares | 79,755,699 |
Return
| Return on Equity | 8.25% |
|---|---|
| Return on Assets | 7.70% |
| Return on Invested Capital | 7.45% |
Valuation & Multiples
| P/E Ratio | 32.17 |
|---|---|
| PEG | -1.19 |
| Price to Sales | 6.62 |
| Price to Book Ratio | 2.72 |
| Enterprise Value to Revenue | 6.12 |
| Enterprise Value to EBIT | 32.42 |
| Enterprise Value to Net Income | 30 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 12.01% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.14%▼ 108.20% |
|---|---|
| Total Invested | $191.37M▼ 93.27% |
| Investors Holding | 86▼ 254.00% |
ESG Score
No data
About Veracyte Inc
CEO: Bonnie Anderson Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending (Medicare/Medicaid reimbursement), which profoundly impacts medical laboratories' revenue, profitability, and market access.
This committee allocates federal funds to agencies like FDA, NIH, and CMS, directly impacting regulatory capacity, research, and crucial reimbursement rates for medical laboratories.
This committee directly regulates the FDA (critical for diagnostic test approvals) and the NIH (key for research funding), both of which are central to medical laboratories like Veracyte.